An outstanding candidate for a human anti-cancer treatment
EBC-46 is a novel natural product small molecule with anticancer activity being developed as a local treatment for solid tumours in humans and companion animals (dogs, cats and horses). EBC-46 was discovered by applying the EcoLogic™ approach to drug discovery from the tropical rainforests of Far North Queensland. EcoLogic™ was developed by QBiotics’ parent entity EcoBiotics.
QBiotics plans to develop EBC-46 as a human pharmaceutical to Clinical Phase II and then seek a development partner for final development and marketing of the drug. QBiotics has already demonstrated very compelling proof-of-concept of the drug's efficacy and safety by successfully treating advanced, spontaneous tumours in companion animals that were considered untreatable with current standards of care. As the principles behind the development of cancer in animals and humans are analogous, it is likely that EBC-46 will have similar effects in humans as in animals.
Potential indications for the drug include:
Testing EBC-46 in vitro against various cancer cell lines, in mouse models of cancer, and in companion animals with cancer, has demonstrated that the drug has broad activity against many different tumour types including:
Skin cancers, such as squamous cell carcinomas (SCC), basal cell carcinomas (BCC) and melanomas;
Head & neck cancers;
Breast cancers;
Prostate cancers; and
Colorectal cancers.
Clinical trials in humans
EBC-46 is currently being evaluated for safety in a Clinical Phase I trial in patients with cutaneous or subcutaneous solid tumours. Such tumours include melanoma, head and neck cancer, SCC and BCC of the skin and Merckel cell carcinoma. In this trial, EBC-46 is delivered locally in a single treatment by direct injection into tumours. The trial is being conducted in Australia by clinicians in Sydney, Melbourne, Brisbane and Adelaide. Details of the trial can be found by accessing the Australian New Zealand Clinical Trial Registry at ANZCTR and entering “QBiotics” in the search window.
(Source: https://qbiotics.com/index.php/human.../ebc-46-humans)
Medical studies:
Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models
Phase 1 dose-escalation study of EBC-46 given by intratumoral injection to patients with refractory cutaneous and subcutaneous tumors
Very promising...
Reply With Quote
Originally Posted by clarky.
